These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 4259147)

  • 1. [BAY a 1040--a highly potent Ca ++ -antagonistic inhibitor of electro-mechanical coupling processes in mammalian myocardium].
    Fleckenstein A; Tritthart H; Döring HJ; Byon KY
    Arzneimittelforschung; 1972 Jan; 22(1):22-33. PubMed ID: 4259147
    [No Abstract]   [Full Text] [Related]  

  • 2. [Electromechanical uncoupling of vascular smooth muscle as the basic principle of coronary dilatation by 4-(2'-nitrophenyl-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid dimethyl ester (BAY a 1040, Nifedipine). 1. The significance of Ca ++ ions for the bioelectrical and mechanical activity of smooth muscle].
    Grün G; Fleckenstein A
    Arzneimittelforschung; 1972 Feb; 22(2):334-44. PubMed ID: 4623697
    [No Abstract]   [Full Text] [Related]  

  • 3. [Effect of BAY a 1040 on oxygen supply of the isolated perfused and arrested guinea pig heart].
    Follert EK
    Arzneimittelforschung; 1972 Feb; 22(2):349-53. PubMed ID: 5067486
    [No Abstract]   [Full Text] [Related]  

  • 4. [The mechanism of coronary dilatating action of nifedipine].
    Kosche F; Raff WK; Lochner W
    Arzneimittelforschung; 1972 Jan; 22(1):39-42. PubMed ID: 5066996
    [No Abstract]   [Full Text] [Related]  

  • 5. Cardiohemodynamic effects of BAY a 1040 in the dog.
    Hashimoto K; Taira N; Chiba S; Hashimoto K; Endo M
    Arzneimittelforschung; 1972 Jan; 22(1):15-21. PubMed ID: 5066992
    [No Abstract]   [Full Text] [Related]  

  • 6. [Pharmacology of 4-(2'-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid dimethyl ester (Nifedipine, BAY a 1040)].
    Vater W; Kroneberg G; Hoffmeister F; Saller H; Meng K; Oberdorf A; Puls W; Schlossmann K; Stoepel K
    Arzneimittelforschung; 1972 Jan; 22(1):1-14. PubMed ID: 4622472
    [No Abstract]   [Full Text] [Related]  

  • 7. [Studies on nifedipine, a coronary vasodilator agent with rapid sublingual effects].
    Raff WK; Kosche F; Lochner W
    Arzneimittelforschung; 1972 Jan; 22(1):33-9. PubMed ID: 5066995
    [No Abstract]   [Full Text] [Related]  

  • 8. Drug-induced changes in cardiac energy.
    Fleckenstein A
    Adv Cardiol; 1974; 12(0):183-97. PubMed ID: 4600368
    [No Abstract]   [Full Text] [Related]  

  • 9. [Comparative studies on the basic Ca2+ antagonistic activities of niludipine (Bay a 7168) and nifedipine (Bay a 1040) on the myocardium, myometrium and vessels of smooth muscles (author's transl)].
    Fleckenstein A; Fleckenstein-Grün G; Byon YK; Haastert HP; Späh F
    Arzneimittelforschung; 1979; 29(2):230-46. PubMed ID: 582136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The calcium-antagonistic fundamental effects of Verapamil on myocardial fibers and smooth muscle cells of the blood vessels].
    Fleckenstein A; Grün G; Byon KY
    Minerva Med; 1975 May; 66(38):1827-37. PubMed ID: 1128823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coronary circulation systemic resistance and capacitance blood vessels of dogs as affected by BAY a 1040.
    Hirakawa S; Ito H; Kondo Y; Watanabe I; Hiei K
    Arzneimittelforschung; 1972 Feb; 22(2):344-9. PubMed ID: 4623698
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of niludipine (Bay a 7168) on the cardiovascular system with a note on its calcium-antagonistic effects.
    Hashimoto K; Takeda K; Katano Y; Nakagawa Y; Tsukada T; Hashimoto T; Shimamoto N; Sakai K; Otorii T; Imai S
    Arzneimittelforschung; 1979; 29(9):1368-73. PubMed ID: 583243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Fundamental cardiac and vascular effects of Ca++-antagonistic coronary drugs].
    Fleckenstein A
    Med Klin; 1975 Oct; 70(42):1665-74. PubMed ID: 1102892
    [No Abstract]   [Full Text] [Related]  

  • 14. Inotropic effects of Nifedipine: a new coronary dilating agent.
    Strauer BE
    Int J Clin Pharmacol; 1974 Mar; 9(2):101-7. PubMed ID: 4827553
    [No Abstract]   [Full Text] [Related]  

  • 15. [The indicative value of central hemodynamic changes following the administration of an o-nitrophenyl-dihydropyridine derivative].
    Schneider KW; Jesse R
    Arzneimittelforschung; 1972 Feb; 22(2):373-7. PubMed ID: 5067490
    [No Abstract]   [Full Text] [Related]  

  • 16. Hemodynamic and therapeutic effect of BAY a 1040 on the patients with ischemic heart disease.
    Hayase S; Hirakawa S; Hosokawa S; Mori N; Kanyama S
    Arzneimittelforschung; 1972 Feb; 22(2):370-3. PubMed ID: 4554632
    [No Abstract]   [Full Text] [Related]  

  • 17. [Fundamental cardiovascular effects of the Ca++ antagonistic coronary drug fendiline (author's transl)].
    Fleckenstein A; Fleckenstein-Grün G; Byon YK
    Arzneimittelforschung; 1977; 27(3):562-71. PubMed ID: 577423
    [No Abstract]   [Full Text] [Related]  

  • 18. [Changed hemodynamics of the left heart under the influence of Nifedipine (BAY a 1040) as compared to nitroglycerin].
    Kaltenbach M; Becker HJ; Kober G; Loos A
    Arzneimittelforschung; 1972 Feb; 22(2):362-5. PubMed ID: 4623699
    [No Abstract]   [Full Text] [Related]  

  • 19. [Influence of extracellular calcium concentration on the effect of coronary dilatators (action mechanism of coronary dilatators)].
    Kosche F; Raff KW; Lochner W
    Pflugers Arch; 1972; 335(1):46-57. PubMed ID: 4627535
    [No Abstract]   [Full Text] [Related]  

  • 20. Proceedings: Further studies on the neutralization of glycosine-induced contractures of coronary smooth muscle by Ca-antagonistic compounds (verapamil, D 600, prenylamine, nifedipine, fendiline or nitrites).
    Fleckenstein A; Fleckenstein-Grün G
    Naunyn Schmiedebergs Arch Pharmacol; 1975; 287 Suppl():R38. PubMed ID: 1143432
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.